Compare TOUR & CYPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TOUR | CYPH |
|---|---|---|
| Founded | 2006 | 2011 |
| Country | China | United States |
| Employees | N/A | 6 |
| Industry | Transportation Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 73.1M | 73.4M |
| IPO Year | 2014 | N/A |
| Metric | TOUR | CYPH |
|---|---|---|
| Price | $7.19 | $0.90 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 95.9K | ★ 2.3M |
| Earning Date | 06-11-2026 | 05-13-2026 |
| Dividend Yield | ★ 17.12% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $17.30 | N/A |
| Revenue Next Year | $14.00 | N/A |
| P/E Ratio | $87.34 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.56 | $0.50 |
| 52 Week High | $7.39 | $3.70 |
| Indicator | TOUR | CYPH |
|---|---|---|
| Relative Strength Index (RSI) | 96.27 | 53.31 |
| Support Level | $0.70 | $0.84 |
| Resistance Level | N/A | $1.01 |
| Average True Range (ATR) | 0.24 | 0.09 |
| MACD | 0.55 | -0.01 |
| Stochastic Oscillator | 100.00 | 35.36 |
Tuniu Corp is an online leisure travel company. The company is engaged in the provision of travel-related services in the People's Republic of China. It offers a large selection of packaged tours, including organized tours and self-guided tours, as well as travel-related services for leisure travelers. The company's organized tours provide pre-arranged itineraries, transportation, accommodations, entertainment, meals, and tour guide services. Its self-guided tours consist of combinations of flights and hotel bookings and other optional add-ons. The company derives almost all of its revenue from PRC.
Cypherpunk Technologies Inc is a privacy technology company focused on implementing a digital asset treasury business anchored by Zcash, which is a cryptographic digital asset that operates on a decentralized, open-source blockchain network known as the Zcash Network. Through its subsidiary, the company is also engaged in developing novel therapies for patients with cancer. The group holds Zcash as part of its digital treasury business and has the following drug candidates under development in its biopharma business: Sirexatamab (DKN-01), a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1; and a preclinical antibody program, FL-501, that is designed to treat cachexia-related indications.